RECORD // Company

ADC Therapeutics SA

Built 2026-11-21T11:41:13Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (2)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • ADC Therapeutics · Ctgov · exact name match to 'ADC Therapeutics SA' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • ADC Therapeutics S.A. · Ctgov · same registered legal name as 'ADC Therapeutics SA' Possible match based on name, not a shared identifier. Compare the records. Compare

4 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-09 · accession 0001628280-26-072178

ItemValuePeriodFormFiledAccessionReport
Revenue$21,716,0003 months ended 2026-09-3010-Q2026-11-090001628280-26-0721782026-11-21 11:41 UTCReport an error
Net income (loss)$-25,304,0003 months ended 2026-09-3010-Q2026-11-090001628280-26-0721782026-11-21 11:41 UTCReport an error
Interest expense$13,733,0003 months ended 2026-09-3010-Q2026-11-090001628280-26-0721782026-11-21 11:41 UTCReport an error
Cash and cash equivalents$189,204,000at 2026-09-3010-Q2026-11-090001628280-26-0721782026-11-21 11:41 UTCReport an error

Negative as reported in the filing.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001771910
Ticker
ADCT
CUSIP
H0036K147
Record ID
sx:sec:0001771910

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

33 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-19SEC EDGAR company profile2026-11-21 11:41 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-19SEC EDGAR company profile2026-11-21 11:41 UTCReport an error
State of incorporationV82026-11-19SEC EDGAR company profile2026-11-21 11:41 UTCReport an error
Fiscal year end (MMDD)12312026-11-19SEC EDGAR company profile2026-11-21 11:41 UTCReport an error
Business addressBIOPOLE, ROUTE DE LA CORNICHE 3B, EPALINGES, V8, 10662026-11-19SEC EDGAR company profile2026-11-21 11:41 UTCReport an error
ExchangesNYSE2026-11-19SEC EDGAR company profile2026-11-21 11:41 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$81,357,0002025-12-3110-K, XBRL Revenues2026-11-21 11:41 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-142,623,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 11:41 UTCReport an error
Total assets (at 2025-12-31)$323,150,0002025-12-3110-K, XBRL Assets2026-11-21 11:41 UTCReport an error
Stockholders' equity (at 2025-12-31)$-185,834,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 11:41 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$261,338,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 11:41 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-141,174,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 11:41 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$264,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 11:41 UTCReport an error
Operating lease liabilities (at 2025-12-31)$1,573,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 11:41 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-09)On November 9, 2026, ADC Therapeutics SA (the “Company”) issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information contained in this Item 2.02 and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall…2026-11-09SEC EDGAR 8-K 0001628280-26-071899 (text as filed, excerpt)2026-11-21 11:41 UTCReport an error
8-K Item 2.02, Results of Operations and Financial (filed 2026-11-04)Condition.2026-11-04SEC EDGAR 8-K 0000950103-26-016945 (text as filed, excerpt)2026-11-21 11:41 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-04)On November 4, 2026, ADC Therapeutics SA (the “Company”) issued a press release and made available a presentation in connection with new and updated data from ZYNLONTA clinical trials which will be shared across multiple abstracts, including five oral presentations, at the 68th American Society of Hematology (ASH) Annual Meeting taking place December 12–15, 2026, in New Orleans, Louisiana, copies of which are attached as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and incorporated by reference herein. The presentation includes preliminary revenue estimates for three and nine months ended September 30, 2026, and preliminary cash and cash equivalents as of…2026-11-04SEC EDGAR 8-K 0000950103-26-016945 (text as filed, excerpt)2026-11-21 11:41 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-04)On November 4, 2026, the Company announced updated data from an abstract at ASH for the LOTIS-7 Phase 1b trial of ZYNLONTA in combination with glofitamab in relapsed or refractory large B cell lymphoma. As of the June 15, 2026 data cutoff date, at the ZYNLONTA 150 µg/kg starting dose + glofitamab: • Patients had received a median of one prior treatment (range: 1-5); 52.4% (n=54) of patients had primary refractory disease. • Among 97 efficacy-evaluable patients, the overall response rate (“ORR”) was 88.7% (n=86) and the complete response rate (“CRR”) was 75.3% (n=73). o 2.1% (n=2) of patients achieved stable disease. o 28 patients converted to complete responses over time, from stable…2026-11-04SEC EDGAR 8-K 0000950103-26-016945 (text as filed, excerpt)2026-11-21 11:41 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-10-13)Private Placement On October 7, 2026, ADC Therapeutics SA (the “Company”) entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $86.6 million (assuming the cash exercise of the pre-funded warrants) private placement (the “Private Placement”). In the private placement, the Company will sell 12,911,347 common shares at $1.4200 per share and pre-funded warrants to purchase 48,088,653 common shares at $1.32400 per pre-funded warrant, which is the price per common share in the private placement minus the exercise price per pre-funded warrant. The private placement is expected to close on October 22, 2026, subject to customary…2026-10-13SEC EDGAR 8-K 0000950103-26-015465 (text as filed, excerpt)2026-11-21 11:41 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-10-13)On October 8, 2026, the Company issued a press release that includes the preliminary net product revenues from sales of ZYNLONTA for the quarter ended September 30, 2026 and the preliminary cash and cash equivalents as of September 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The ZYNLONTA net product revenues and cash and cash equivalents figures are preliminary and unaudited and reflect the Company’s estimated financial results. In preparing this information, management made a number of complex and subjective judgments and estimates about the appropriateness of certain reported amounts and…2026-10-13SEC EDGAR 8-K 0000950103-26-015465 (text as filed, excerpt)2026-11-21 11:41 UTCReport an error
8-K Item 3.02, Unregistered Sales of Equity Securities (filed 2026-10-13)The information set forth under Item 1.01 of this Current Report on Form 8-K with regards to the Private Placement, the Lender Warrants and the HCR Warrants is incorporated by reference in this2026-10-13SEC EDGAR 8-K 0000950103-26-015465 (text as filed, excerpt)2026-11-21 11:41 UTCReport an error
8-K Item 2.02, Results of Operations and Financial (filed 2026-08-13)Condition. On August 13, 2026, ADC Therapeutics SA (the “Company”) issued a press release announcing the Company’s financial results for the three and six months ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information contained in this Item 2.02 and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act…2026-08-13SEC EDGAR 8-K 0000950103-26-012287 (text as filed, excerpt)2026-11-21 11:41 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-08-13)On August 13, 2026, the Company made available a presentation, a copy of which is attached as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference herein. The information contained in this Item 7.01 and Exhibit 99.2 shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.2026-08-13SEC EDGAR 8-K 0000950103-26-012287 (text as filed, excerpt)2026-11-21 11:41 UTCReport an error
Largest institutional holder #1 (13F as filed): Nantahala Capital Management, LLC$26,378,0342026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:41 UTCReport an error
Largest institutional holder #2 (13F as filed): Redmile Group, LLC$12,333,5802026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:41 UTCReport an error
Largest institutional holder #3 (13F as filed): TCG Crossover Management, LLC$12,187,4872026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:41 UTCReport an error
Largest institutional holder #4 (13F as filed): Prosight Management, LP$8,372,4812026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:41 UTCReport an error
Largest institutional holder #5 (13F as filed): BlackRock, Inc.$7,511,5002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:41 UTCReport an error
Largest institutional holder #6 (13F as filed): Point72 Asset Management, L.P.$3,904,5842026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:41 UTCReport an error
Largest institutional holder #7 (13F as filed): MILLENNIUM MANAGEMENT LLC$3,102,5022026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:41 UTCReport an error
Largest institutional holder #8 (13F as filed): CITADEL ADVISORS LLC$2,197,0482026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:41 UTCReport an error
Largest institutional holder #9 (13F as filed): GOLDMAN SACHS GROUP INC$2,048,4342026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:41 UTCReport an error
Largest institutional holder #10 (13F as filed): STATE STREET CORP$1,803,8452026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:41 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.